Landauer reports revenue of $36.7 million for first quarter 2013

Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2013 first quarter ended December 31, 2012.

Fiscal 2013 First Quarter Highlights

• Revenue of $36.7 million in the first quarter of fiscal 2013
• First fiscal quarter 2013 operating income of $6.7 million includes IT platform enhancement expense ($1.2 million) and non-cash stock based compensation ($0.7 million)
• Net income of $4.9 million, or $0.52 per diluted share, included $0.06 per diluted share of IT platform enhancement, and non-cash stock based compensation expenses
• EBITDA of $11.5 million for fiscal 1Q13
• Company continued successful stabilization of IT platform following fiscal 4Q12 launch
• Company reaffirms fiscal 2013 guidance

"During the quarter, we focused on several strategic initiatives to further our competitive positioning and long-term growth.  Our IT systems initiative is well into the stabilization phase after a successful launch and opportunities in the military and emergency response markets have continued to expand with Radwatch system revenue in the quarter," said Bill Saxelby, President and CEO of Landauer. "We continued to make investments in technology which we believe will lead to new growth opportunities and we strengthened our human capital across a variety of key functions. These strategic efforts during the quarter, combined with our expectations and the opportunities that we see over the remainder of the year, leave us well positioned to achieve our fiscal 2013 guidance."

First Fiscal Quarter Financial Overview and Business Segment Results

Revenues for the first fiscal quarter of 2013 were $36.7 million. The Medical Physics segment and the Medical Products segment contributed an increase of $0.2 million and $0.5 million, respectively due to their acquisitions over prior year. The Radiation Measurement segment experienced a decrease of $0.6 million. Revenue in the quarter included $1.7 million of Radwatch System sales, primarily to the U.S. military, while the prior year included the benefit of $2.0 million in InLight equipment sales into the military market. Consolidated revenue in the quarter was negatively affected $0.2 million by currency fluctuation, as compared with the prior year period, principally due to weakness in the Euro and Real against the U.S. dollar.

Gross margins were 54.8 percent for the first fiscal quarter of 2013, compared with 59.3 percent for the first fiscal quarter of 2012. The decrease in the gross margin was primarily due to higher costs associated with the new IT platform enhancement, as a portion of depreciation is now allocated to cost of sales since the project went operational during the fiscal fourth quarter of 2012, representing $0.5 million increase; as previously capitalized investment began its scheduled depreciation with a portion related to manufacturing production being allocated in cost of sales.  Additional cost of sales in the quarter includes $0.4 million of ongoing IT system support expenses, over the prior year fiscal quarter. In addition, in the prior fiscal year quarter the Medical Physics segment had a significant level of commissioning sales, which are episodic in nature with that business operating on a relative fixed margin model. 

Total selling, general and administrative expenses for the first fiscal quarter of 2013 were $13.4 million, an increase of $1.0 million, or 8.3 percent, compared to $12.4 million for the same quarter in fiscal 2012.    For the first fiscal quarter of 2013, total selling, general and administrative included $0.7 million IT platform enhancement and $0.7 million of non-cash stock based compensation expenses. This compares with the $12.4 million reported for the first fiscal quarter of 2012, while the current quarter reflects $0.5 million increase in customer service related expenses and $0.3 million increase in IT platform enhancement related expenses.  The prior year first fiscal quarter of 2012 included $0.8 million of non-cash stock based compensation related expenses.  During the fourth quarter of 2012 the IT platform enhancement project successfully went operational and the balance of the above mentioned capitalized investment began its scheduled depreciation with a portion related to the non-manufacturing portion allocated to SG&A expenses, an increase of $0.3 million.

Operating income for the first fiscal quarter of 2013 was $6.7 million, a decrease of $0.9 million, or 11.8 percent compared with operating income of $7.6 million for the same quarter in fiscal 2012. Operating income, adjusted for non-recurring acquisition and reorganization expenses, IT platform enhancement related expenses, and non-cash stock based compensation expenses, for the first fiscal quarter of 2013 was $7.6 million, a 27.5 percent decrease, compared with adjusted operating income on a relative basis of $10.5 million for the first fiscal quarter of 2012.

Interest expense, net of investment income in the quarter, increased $0.4 million associated with borrowings to acquire IZI in the first fiscal quarter of 2012.

The effective tax rate for the first fiscal quarter of 2013 and 2012 was 31.1 percent and 35.0 percent, respectively. The decrease in effective tax rate was due primarily to a change in the mix of earnings based on geographic location of the Company's operations in various jurisdictions and the specific legal entities subject to taxation in those jurisdictions.

Net income for the first fiscal quarter ended December 31, 2012 was $4.9 million, or $0.52 per diluted share, which is consistent with the first fiscal quarter of 2012.

EBITDA for the fiscal first quarter 2013 was $11.5 million compared with $10.6 million in the comparable prior year period. The increase was due primarily to additional interest expense and depreciation offset slightly by lower tax expense.  Adjusted EBITDA was $12.4 million compared to the prior year period Adjusted EBITDA of $13.5 million. A reconciliation of net income to EBITDA and Adjusted EBITDA is included in the attached financial exhibits.

Radiation Measurement Segment

Radiation Measurement revenues for the first fiscal quarter of 2013 decreased 2.2 percent, or $0.6 million, from the first fiscal quarter of 2012 to $26.4 million.  The decrease in the quarter was primarily due to decreases at international subsidiaries over prior year first fiscal quarter.

Radiation Measurement operating income for the first fiscal quarter of 2013 decreased to $5.3 million, or 16.3 percent, from $6.3 million in the comparable prior year period.  The decrease in operating income was due to increased IT expenses related to the company's IT platform enhancement of $1.2 million, decreased revenues from international subsidiaries of $0.4 million, additional customer service support of $0.5 million, additional manufacturing costs of $0.4 million, which was offset by prior year first quarter acquisition costs of $1.8 million.  Corporate expenses for shared functions are recognized in the Radiation Measurement segment where they have been reported historically.  Acquisition and reorganization costs are not allocated to the segments.  As the Company's business model evolves in increased complexity, management may determine it necessary to change this reporting practice to reflect any appropriate allocations.

Medical Physics Segment

Medical Physics revenues for the first fiscal quarter of 2013 increased 2.0 percent, or $0.2 million, from the comparable period in fiscal 2012 to $7.6 million due to the impact of acquired companies.  The Medical Physics segment operating income was $0.8 million, or 10.4 percent of revenues, as compared to $0.9 million, or 12.0 percent of revenues, in the first fiscal quarter of 2012. 

Medical Products Segment       

Medical Products revenues for the first fiscal quarter of 2013 increased 22.7 percent, or $0.5 million, from the first fiscal quarter of 2012 to $2.7 million. Medical Products operating income for the first fiscal quarter of 2013 was $0.7 million, or 24.9 percent of revenues, as compared to $0.4 million, or 16.7 percent of revenues, in the first fiscal quarter of 2012.  The increase in revenue and operating income is due primarily to a full quarter results in fiscal 2013 versus only 1.5 months in fiscal 2012.

Balance Sheet

Landauer ended the first fiscal quarter of 2013 with total assets of $300.8 million, a decrease of $1.3 million compared to total assets of $302.1 million at the end of fiscal 2012.  The Company completed the quarter with $16.5 million of cash and cash equivalents on the balance sheet and unused borrowing capacity of $29.2 million under its current $175 million credit facility, which provides adequate liquidity to meet its current and anticipated obligations.  Net operating cash flow generated during the first fiscal quarter of 2013 was $2.1 million.   

Fiscal 2013 Outlook

Landauer's business plan for fiscal 2013 currently anticipates aggregate revenues for the year to be in the range of $164 to $168 million.  The business plan also anticipates a blended effective tax rate for the full fiscal year in the range of 32 percent to 35 percent.

Based upon the above assumptions, the Company anticipates reported net income for fiscal 2013 in the range of $21 to $23 million and Adjusted EBITDA expected for fiscal 2013 in the range of $55 to $58 million.

SOURCE Landauer, Inc.